4//SEC Filing
LYNCH TIMOTHY P 4
Accession 0001181431-10-010751
CIK 0001282393other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 8:18 PM ET
Size
15.3 KB
Accession
0001181431-10-010751
Insider Transaction Report
Form 4
LYNCH TIMOTHY P
Director
Transactions
- Disposition to Issuer
Director Stock Option (Right to Buy)
2010-02-16−35,000→ 0 totalExercise: $2.50Exp: 2016-07-20→ Common Stock (35,000 underlying) - Disposition from Tender
Common Stock
2010-02-16$5.45/sh−45,454$247,724→ 0 total - Disposition to Issuer
Director Stock Option (Right to Buy)
2010-02-16−10,000→ 0 totalExercise: $3.61Exp: 2019-12-10→ Common Stock (10,000 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
2010-02-16−10,000→ 0 totalExercise: $1.10Exp: 2018-12-20→ Common Stock (10,000 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
2010-02-16−6,500→ 0 totalExercise: $4.50Exp: 2017-02-01→ Common Stock (6,500 underlying)
Footnotes (5)
- [F1]These shares were tendered to Vine Acquisition Corp. (the "Purchaser") pursuant to Purchaser's offer to purchase all of the outstanding shares of BioForm Medical, Inc. (the "Issuer") at a cash purchase price of $5.45 per share, without interest thereon, and less any applicable withholding taxes, subject to the terms described in the Offer to Purchase filed with the Securities and Exchange Commission on January 15, 2010 (the "Tender Offer") and the Agreement and Plan of Merger, dated as of December 31, 2009, by and among Merz GmbH & Co. KGaA, the Purchaser and the Issuer. Such shares were purchased by the Purchaser pursuant to the Tender Offer on February 16, 2010.
- [F2]The shares underlying these options, which were accelerated and became vested in connection with the closing of the Tender Offer and the fact that the reporting person ceased to be a director of the Issuer, were canceled in exchange for a cash payment of $18,400.00 representing the number of vested shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.
- [F3]The shares underlying these options, which were accelerated and became vested in connection with the closing of the Tender Offer and the fact that the reporting person ceased to be a director of the Issuer, were canceled in exchange for a cash payment of $43,500.00 representing the number of vested shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.
- [F4]The shares underlying these options, which were fully vested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for a cash payment of $103,250.00, representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.
- [F5]The shares underlying these options, which were fully vested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for a cash payment of $6,175.00, representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.
Documents
Issuer
BIOFORM MEDICAL INC
CIK 0001282393
Entity typeother
Related Parties
1- filerCIK 0001270925
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 8:18 PM ET
- Size
- 15.3 KB